Moderna Inc (MRNA)
Profitability ratios
Return on sales
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | -5.77% | 18.40% | 42.64% | 55.91% | 64.55% | 73.83% | 77.78% | 80.58% | 81.74% | 82.08% | 81.79% | 83.73% | 75.29% | 55.63% | 15.77% | -54.28% | -39.50% | -2.97% |
| Operating profit margin | -62.73% | -29.32% | 4.82% | 32.05% | 48.90% | 61.94% | 68.02% | 71.93% | 71.98% | 64.33% | 54.40% | 23.21% | -95.02% | -251.39% | -484.75% | -1,027.19% | -907.95% | -697.70% |
| Pretax margin | -58.33% | -25.94% | 7.68% | 33.47% | 49.71% | 62.32% | 68.12% | 71.92% | 71.92% | 64.27% | 54.42% | 23.43% | -92.65% | -242.52% | -460.07% | -970.41% | -855.35% | -652.75% |
| Net profit margin | -69.75% | -38.14% | 11.33% | 31.77% | 43.41% | 55.00% | 61.12% | 64.77% | 66.06% | 59.68% | 49.79% | 21.89% | -93.03% | -242.74% | -459.45% | -968.54% | -853.69% | -652.31% |
Moderna Inc's profitability ratios have shown a significant fluctuation over the past eight quarters. The gross profit margin has been on a declining trend, starting at a high of 84.77% in Q1 2022 and dropping to 31.47% in Q4 2023. This indicates a decrease in the company's ability to generate profits after accounting for the cost of goods sold.
The operating profit margin and pretax margin have also shown a declining trend, with both ratios becoming negative in the most recent quarter, Q4 2023. The company's operating profit margin went from a high of 71.93% in Q1 2022 to -61.90% in Q4 2023, indicating that the company's operating expenses have outpaced its revenues. Similarly, the pretax margin was positive in Q1 2022 at 71.92% but turned negative to -57.56% in Q4 2023, highlighting a deterioration in the company's profitability before taxes.
Moreover, the net profit margin has also been on a downward trajectory, decreasing from 64.77% in Q1 2022 to -68.84% in Q4 2023. This indicates a significant decrease in Moderna Inc's ability to generate profits after all expenses, including taxes and interest payments, have been considered. Overall, the declining trend in all profitability ratios suggests challenges in Moderna Inc's ability to maintain profitability and efficiency in its operations.
Return on investment
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | -23.01% | -13.70% | 2.34% | 20.01% | 36.43% | 50.85% | 60.06% | 58.88% | 53.90% | 36.38% | 23.64% | 4.99% | -10.40% | -13.30% | -14.75% | -25.93% | -34.39% | -35.78% |
| Return on assets (ROA) | -25.58% | -17.82% | 5.52% | 19.83% | 32.34% | 45.15% | 53.97% | 53.02% | 49.46% | 33.75% | 21.64% | 4.71% | -10.18% | -12.84% | -13.98% | -24.45% | -32.34% | -33.45% |
| Return on total capital | -30.60% | -19.81% | 3.03% | 25.59% | 49.26% | 73.64% | 86.97% | 95.21% | 94.00% | 75.18% | 56.95% | 16.52% | -29.79% | -22.41% | -17.45% | -32.66% | -46.53% | -45.60% |
| Return on equity (ROE) | -34.03% | -25.76% | 7.12% | 25.36% | 43.73% | 65.39% | 78.15% | 85.73% | 86.26% | 69.75% | 52.13% | 15.58% | -29.17% | -21.64% | -16.54% | -30.80% | -43.74% | -42.63% |
Moderna Inc's profitability ratios indicate a volatile trend over the quarterly periods analyzed. The operating return on assets (Operating ROA) fluctuated from negative to positive levels, ranging from -23.01% in Q4 2023 to 60.06% in Q2 2022. This indicates inconsistent operational efficiency in generating profits from its assets.
Similarly, the return on assets (ROA) varied from -25.58% in Q4 2023 to 53.97% in Q2 2022, showing inconsistency in its ability to generate earnings relative to its total assets.
Return on total capital also saw fluctuations, with values ranging from -29.38% in Q4 2023 to 90.92% in Q1 2022, indicating varying levels of profitability in relation to the total invested capital.
Furthermore, return on equity (ROE) displayed a similar pattern, with values oscillating between -34.03% in Q4 2023 and 85.73% in Q1 2022. This suggests changing levels of profitability in relation to shareholder's equity.
Overall, the profitability ratios reflect Moderna Inc's inconsistent performance in profitability over the quarters, highlighting the company's need to focus on stabilizing and improving its profitability metrics to ensure sustainable long-term financial health.